^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | lifirafenib (BGB-283) (EGFR inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Published date:
03/17/2020
Excerpt:
One patient with B-RAF-mutated melanoma achieved complete response, and 8 patients with B-RAF mutations had confirmed objective responses: B-RAFV600E/K melanoma (n = 5, including 1 patient treated with prior B-RAF/MEK inhibitor therapy), B-RAFV600E thyroid cancer/papillary thyroid cancer (PTC; n = 2), and B-RAFV600E low-grade serous ovarian cancer (LGSOC; n = 1)...
DOI:
10.1200/JCO.19.02654
